Arabic Arabic English English French French German German
dark

Boehringer Ingelheim and OSE Immunotherapeutics to Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021

OSE Immunotherapeutics SA announced that promising data from dose escalation Phase 1 of selective SIRPα inhibitor BI 765063 in patients with advanced solid tumors will be presented at the 2021 European Society for Medical Oncology Virtual Conference to be held on September 16 – 21, 2021. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

ClearDATA Partners with Interlace Health to Safeguard Data for Zero-Touch Patient Intake Solution

Next Post

Transgene Announces Upcoming Investor Meetings – Sep 13, 2021

Related Posts
Total
0
Share